{"denoms":[{"counts":[{"groupId":"BG000","value":"17"}],"units":"Participants"}],"groups":[{"description":"All participants enrolled.\n\nBortezomib: Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m\\^2 on days 1, 8, 15, and 22 of each 42 day cycle.\n\nPatients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle.","id":"BG000","title":"Arm -1 Bortezomib"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"41","upperLimit":"79","value":"61"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}]}